Vulvovaginal Candidiasis

Ibrexafungerp for Vulvovaginal Candidiasis

Ibrexafungerp for Vulvovaginal Candidiasis

Ibrexafungerp (formerly SCY-078), if approved, may represent an optimal therapy for the treatment of acute vulvovaginal candidiasis (VVC) and for prevention of recurrence. Ibrexafungerp is orally administered and is extensively distributed into vaginal tissues. It is also fungicidal, with a broad spectrum of activity and enhanced activity in the acidic pH at the site of infection.

Acute VVC and recurrent VVC are serious conditions with significant morbidity and with very limited oral treatment options. No product is approved for the prevention of recurrent VVC, and current treatment alternatives have significant limitations, particularly in patients with other comorbidities and those who are taking certain concomitant medications, are pregnant or are experiencing episodes caused by an azole-resistant micro-organism.

What is Vulvovaginal Candidiasis?

VVC, commonly known as a "vaginal yeast infection," is the second most common cause of vaginitis and is usually caused by Candida spp. It affects approximately 70-75% of women at least once in their lifetime, with 40-50% of these women experiencing more than one episode. The majority of VVC episodes are uncomplicated cases with sporadic mild-to-moderate infections. The remaining complicated cases are severe and/or recurring infections.

Market Need

VVC can be associated with substantial morbidity, including significant genital discomfort, reduced sexual pleasure, psychological distress and loss of productivity. Diagnosis and treatment, combined with lost productivity, are estimated to cost $1.0 billion per year in the U.S. Current treatments for VVC include over-the-counter (OTC) topical azole antifungals and the prescription oral azole antifungal, fluconazole.

  • Fluconazole is the only orally-administered antifungal currently approved for VVC in the U.S., with a reported therapeutic cure rate of 55%.
  • Management of VVC during pregnancy and treatment of moderate-to-severe VVC, recurrent VVC and VVC caused by fluconazole-resistant Candida are not fully addressed by oral fluconazole.
  • There are no oral alternatives for VVC patients who do not respond to or tolerate fluconazole, and there are no FDA-approved products for the treatment of recurrent VVC.

We believe that ibrexafungerp, if approved for the treatment of VVC, may provide a significant benefit for patients not satisfied with existing therapies

~70-75% of women of reproductive age will have at least one episode of VVC during their lifetime
~40-45% of women will experience two or more episodes of VVC
~650K patients suffer from recurrent complicated VVC (at least four episodes during a 12-month period)

*Data on File (2015 IMS Consulting Group study, commissioned by SCYNEXIS).

Ibrexafungerp Key Attributes vs. SOC
New MoA
  • Fungicidal (kills the pathogen)
  • Broad spectrum (including fluconazole-resistant Candida strains)
  • Enhanced activity at low vaginal pH
  • High vaginal tissue penetration
Favorable Safety Profile
  • No observed safety signals (>1,000 subjects exposed)
  • No evidence of embryo/fetal risk
  • No evidence of liver toxicity or QT prolongation
Convenient Dosing
  • Novel oral therapy
  • Single-day dose for treatment of VVC
Ibrexafungerp Potential Targeted Patient Population
Mild-to-severe VVC patients
  • Patients where the physician wants to try another therapy with a new MoA
  • Physicians concerned about Candida-resistant strains
  • Fluconazole failures
  • Recurrent patients
  • Complicated patients with co-morbidities
  • Women of child-bearing age where physicians prefer an agent that has shown no fetal toxicity in preclinical studies

“Many of the unresolved clinical issues in managing women with recurrent VVC would disappear if truly fungicidal drugs and regimens were available.”

- Dr. Jack D. Sobel
Current Infectious Disease Reports 2006,8:481–486

Clinical Trial Results

Clinical experience to date has shown promising evidence of the antifungal activity of Ibrexafungerp (formerly SCY-078) in patients with Candida infections.

Identified 600 mg dose as having optimal combination of activity and tolerability - plan to move this into Phase 3.

  • High clinical and mycological activity vs. Candida
  • Sustained clinical response over time
    • Data suggests improved sustained benefit relative to the standard of care
  • Clinical data consistent with pre-clinical evaluations of SCY-078’s attributes:
    • Fungicidal vs. Candida
    • High vaginal tissue penetration
    • Enhanced activity at the low pH characteristic of the vaginal environment
  • Safe and well-tolerated
    • No serious AEs or discontinuations
    • Gastrointestinal (GI) events were mild to moderate and of short-duration

Phase 3 Study for the
Treatment of VVC (VANISH-303)

( Identifier: NCT03734991)

  • Goal: To evaluate the efficacy and safety of oral ibrexafungerp versus placebo in subjects with acute vulvovaginal candidiasis
  • Design: Randomized, multi-center, double-blind, placebo-controlled
  • Enrollment:
    • 376 female patients (age 12 and older) with acute VVC (S&S ≥4)*
    • 286 patients in the modified Intent-To-Treat (mITT = culture-confirmed infection)
  • Primary efficacy endpoint: Clinical cure: Complete resolution of all signs and symptoms (all scores = 0) at Test-of-Cure (TOC) visit (Day 10)
  • Selected Secondary efficacy parameters:
    • % of subjects with mycological eradication (negative culture) at TOC visit
    • % of subjects with clinical improvement (partial or complete resolution of signs and symptoms with total composite score no greater than 1) at the TOC visit
  • Safety and Tolerability

*Signs and symptoms

    • By investigator: Edema (swelling of tissue), Erythema (redness), Excoriation (fissures)
    • By patient: Burning, Itching, Irritation
    • Scoring scale: 0 (absent), 1 (mild), 2 (moderate), 3 (severe)
    • Score range on scale: 0-18

Key Findings

Ibrexafungerp achieved superiority versus placebo:

  • Clinical cure at TOC (primary) 50.5% – p=0.001
  • Mycological eradication at TOC (secondary) 49.5% – p<0.001
  • Signs & Symptoms ≤1 at TOC (secondary) 64.4% – p<0.001

Ibrexafungerp was generally safe and well-tolerated

  • GI events were predominantly mild and of short duration

Phase 2b Dose-Finding Study (DOVE)

( Identifier: NCT03253094)

  • Goal: Identify optimal oral dose of SCY-078 for Phase 3
  • Design: Randomized, multi-center, double-blind, active-controlled, dose-finding study
  • Enrollment:
    • 186 female patients with moderate-to-severe acute VVC (S&S ≥7)*
    • 153 patients in the modified Intent-To-Treat (mITT = culture-confirmed infection)
Treatment Groups
Total Dose in mg
Reginmen ITT / mITT
(# of patients)
600mg SCY-078 300mg BID for 1 day 30 / 27
750mg SCY-078 750mg QD for 1 day 32 / 26
900mg SCY-078 450mg BID for 1 day 28 / 21
900mg SCY-078 150mg BID for 3 days 32 / 29
1080mg SCY-078 300mg BID for 3 days 32 / 26
150mg Fluconazole 150mg QD for 1 day 32 / 24
  • Primary efficacy endpoint: Clinical cure: Resolution of all signs and symptoms (all scores = 0) without further antifungal treatment at Test-of-Cure (TOC) visit (Day 10)
  • Secondary efficacy parameters:
    • Clinical outcome at Follow-Up (FU) visit (Day 25)
    • Mycological eradication (negative culture) at Days 10 and 25
  • Use of antifungal rescue therapy and changes from baseline signs and symptoms score also evaluated
  • Signs and symptoms:
    • By investigator: Edema (swelling of tissue), Erythema (redness), Excoriation (fissures)
    • By patient: Burning, Itching, Irritation
    • Scoring scale: 0 (absent), 1 (mild), 2 (moderate), 3 (severe)
    • Score range on scale: 0-18

Results based on mITT population | * No rescue antifungal use.

Signs and Symptoms [S&S] score defined as a composite endpoint of the subject’s reported symptoms (burning, itching and irritation) and the investigator’s assessed signs (swelling, redness and excoriations). Each sign and symptom can be absent, mild, moderate or severe, with a corresponding score from 0 to 3. The total composite scale goes from 0 to 18 points.

Results based on mITT population.

Mean signs and symptoms score based on 0-18 scale.

P value based on change from baseline score mean difference between SCY-078 600mg and FLU.

Clinical Development Plan

SCYNEXIS anticipates that the dose regimen selected from the DOVE study will be subsequently evaluated in Phase 3 studies following an End-of-Phase 2 meeting with the FDA. SCYNEXIS expects to initiate the Phase 3 clinical program in the fourth quarter of 2018 and file a New Drug Application (NDA) for acute VVC in 2020.






Acute Vulvovaginal Candidasis

Phase 2b DOVE Results

Two Phase 3 Acute VVC Studies

Potential NDA filing in H2:2020

Recurrent Vulvovaginal Candidasis

One Phase 3 Recurrent VVC Study

Potential sNDA filing in 2021


Preliminary assessment (to be further validated). SCYNEXIS Primary HCPs and Payers Market Research.

CDC: Vaginal Candidiasis.